Aspen Neuroscience shares fall on Nasdaq debut after IPO
The drug developer completed a U.S. IPO before its shares fell on their first day of Nasdaq trading.
The drug developer completed a U.S. IPO before its shares fell on their first day of Nasdaq trading.